Mirum Pharmaceuticals, Inc. (MIRM)


-1.12 (-3.76%)
Symbol MIRM
Price $28.65
Beta 1.252
Volume Avg. 0.59M
Market Cap 1.097B
Shares () -
52 Week Range 17.315-33.393
1y Target Est -
DCF Unlevered MIRM DCF ->
DCF Levered MIRM LDCF ->
ROE 121.72% Strong Buy
ROA -39.75% Strong Sell
Operating Margin -
Debt / Equity -61.94%
P/E -6.47 Strong Sell
P/B -2.20 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest MIRM news

Mr. Christopher Peetz
NASDAQ Global Market

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.